Does PEMBROLIZUMAB Cause Hypopituitarism? 203 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 203 reports of Hypopituitarism have been filed in association with PEMBROLIZUMAB (KEYTRUDA). This represents 0.2% of all adverse event reports for PEMBROLIZUMAB.
203
Reports of Hypopituitarism with PEMBROLIZUMAB
0.2%
of all PEMBROLIZUMAB reports
22
Deaths
134
Hospitalizations
How Dangerous Is Hypopituitarism From PEMBROLIZUMAB?
Of the 203 reports, 22 (10.8%) resulted in death, 134 (66.0%) required hospitalization, and 25 (12.3%) were considered life-threatening.
Is Hypopituitarism Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for PEMBROLIZUMAB. However, 203 reports have been filed with the FAERS database.
What Other Side Effects Does PEMBROLIZUMAB Cause?
Malignant neoplasm progression (10,111)
Death (4,744)
Diarrhoea (4,251)
Fatigue (3,833)
Off label use (3,416)
Product use in unapproved indication (3,191)
Pyrexia (3,155)
Rash (2,900)
Nausea (2,670)
Decreased appetite (2,486)
What Other Drugs Cause Hypopituitarism?
NIVOLUMAB (455)
IPILIMUMAB (391)
CARBOPLATIN (89)
ATEZOLIZUMAB (71)
SOMATROPIN (67)
PACLITAXEL (64)
BEVACIZUMAB (45)
PREDNISONE (41)
DURVALUMAB (38)
LENVATINIB (34)
Which PEMBROLIZUMAB Alternatives Have Lower Hypopituitarism Risk?
PEMBROLIZUMAB vs PEMETREXED
PEMBROLIZUMAB vs PEMIGATINIB
PEMBROLIZUMAB vs PENICILLAMINE
PEMBROLIZUMAB vs PENICILLIN
PEMBROLIZUMAB vs PENICILLIN G